Federal contract award
HHSO100201700016C
IGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $695.7M |
| Current contract value | $695.7M |
| Potential contract value / ceiling | $759.1M |
| Start date | Sep 30, 2017 |
| Current end date | Sep 29, 2027 |
| Potential end date | Sep 29, 2027 |
| Latest award activity | Jul 30, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 17 of 17 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 30, 2026 | P00017 | $2.7M | INMAZEB EBOLA THERAPEUTICS |
| Aug 6, 2025 | P00016 | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.4 AND F.4 |
| Dec 6, 2024 | P00015 | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.2.1., ARTICLE C.1., ARTICLE F.4, , ARTICLE G.4. AND THE STATEMENT OF WORK. |
| Nov 7, 2023 | P00014 | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.2.2., B.4.Q., ARTICLE C.1., ARTICLE F.4, AND THE STATEMENT OF WORK. ADD ARTICLE B.4.R., ARTICLE H.31., AND FAR CLAUSE 52.204-27. |
| Dec 14, 2022 | P00013 | $0 | EBOLA THERAPEUTICS |
| Sep 29, 2022 | P00011 | $0 | EBOLA THERAPEUTICS |
| Jul 29, 2021 | P00010 | $0 | EBOLA THERAPEUTICS |
| Apr 20, 2021 | P00009 | $0 | EBOLA THERAPEUTICS |
| Jul 25, 2020 | P00008 | $344.6M | EBOLA THERAPEUTICS |
| May 6, 2020 | P00007 | $-67.9K | EBOLA THERAPEUTICS |
| Apr 23, 2020 | P00006 | $47.3M | EBOLA THERAPEUTICS |
| Sep 25, 2019 | P00005 | $22.8M | EBOLA THERAPEUTICS |
| May 22, 2019 | P00004 | $131.8M | IGF::OT::IGF |
| Aug 13, 2018 | 3 | $52.6M | IGF::OT::IGF |
| May 9, 2018 | 2 | $25.9M | IGF::OT::IGF |
| Feb 13, 2018 | 1 | $27.7M | IGF::OT::IGF |
| Sep 28, 2017 | 0 | $40.4M | IGF::OT::IGF |
Estimated positioning window
Oct 25, 2026 – Mar 29, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-09-29 (339 days from calculation)
- +35 points
- 40 historical awards in this buyer and category group
- +15 points
- 17 recorded award transactions
- +10 points
- Latest award action: 2026-07-30
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.